MSB 2.10% $1.17 mesoblast limited

Ann: Change of Director's Interest Notice - Silviu Itescu, page-128

  1. 7,518 Posts.
    lightbulb Created with Sketch. 6772
    No, not for regulatory approval, but the compassionate use program does prove the Physicians using it believe it does work and the FDA do not consider it blatantly unsafe, nor there any decent alternative for its patients to use, per compassionate use FDA guidelines:

    Patient has a serious or immediately life-threatening disease or condition.
    There is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition.
    Patient enrollment in a clinical trial is not possible.
    Potential patient benefit justifies the potential risks of treatment.
    Providing the investigational medical product will not interfere with investigational trials that could support a medical product’s development or marketing approval for the treatment indication.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.17
Change
-0.025(2.10%)
Mkt cap ! $1.330B
Open High Low Value Volume
$1.18 $1.22 $1.15 $6.344M 5.404M

Buyers (Bids)

No. Vol. Price($)
1 8683 $1.16
 

Sellers (Offers)

Price($) Vol. No.
$1.17 32999 1
View Market Depth
Last trade - 16.10pm 15/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.